Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OM-85 to Prevent Respiratory Infections in Older At Risk Patients
NCT06655272Phase 4Recruiting
- Sponsor
- Università Campus Bio-Medico di Roma
- Start
- Feb 2025
- Primary completion
- Jan 2026
- Modality
- Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in respiratory tract infection (RTI) comparing OM-85 with Placebo (2 arms). Primary endpoint: Incidence of lower respiratory tract infections at 12 months. Started Feb 2025; status: recruiting.
02
Drugs
OM-85
03
Conditions
respiratory tract infection (RTI)
Beyond the preview
Go deeper on NCT06655272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06655272.